Newborn screening for metabolic diseases: saving children's lives and improving outcomes

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• Newborn screening began in the 1960s for phenylketonuria, with criteria for adding conditions based on prevalence, treatability, and cost.
• Congenital hypothyroidism and congenital adrenal hyperplasia were later additions to newborn screening panels.
• The development of tandem mass spectrometry revolutionized screening, allowing for the inclusion of numerous metabolic disorders, some not meeting original criteria.

Purpose of the Study:

• To discuss the current landscape of newborn screening for metabolic diseases.
• To report on the clinical outcomes of infants identified through newborn screening programs.

Main Methods:

• Historical review of newborn screening program development.
• Analysis of diagnostic advancements, particularly tandem mass spectrometry.
• Evaluation of clinical outcome measures for screened infants.

Main Results:

• Newborn screening has expanded beyond initial criteria due to technological advancements.
• Tandem mass spectrometry facilitates the detection of a wider array of metabolic disorders.
• Clinical outcomes for screened patients are a key focus of current programs.

Conclusions:

• Newborn screening for metabolic diseases is a dynamic field, continually evolving with technology.
• The inclusion criteria for screening have broadened, necessitating ongoing evaluation of effectiveness.
• Assessing clinical outcomes is crucial for understanding the impact of expanded newborn screening.